Year |
Citation |
Score |
2019 |
Hu S, Marineau JJ, Rajagopal N, Hamman KB, Choi YJ, Schmidt DR, Ke N, Johannessen L, Bradley MJ, Orlando DA, Alnemy SR, Ren Y, Ciblat S, Winter DK, Kabro A, et al. Discovery and characterization of SY-1365, a selective, covalent inhibitor of CDK7. Cancer Research. PMID 31064851 DOI: 10.1158/0008-5472.Can-19-0119 |
0.377 |
|
2019 |
Hu S, Marineau J, Hamman K, Bradley M, Savinainen A, Alnemy S, Rajagopal N, Orlando D, Chuaqui C, Olson E. Abstract 4421: SY-5609, an orally available selective CDK7 inhibitor demonstrates broad anti-tumor activity in vivo Cancer Research. 79: 4421-4421. DOI: 10.1158/1538-7445.Sabcs18-4421 |
0.353 |
|
2019 |
Ke N, Johannessen L, Rajagopal N, Orlando D, Carulli J, Hodgson G. Abstract 4409: Prospective identification of RB pathway alterations predict response to SY-1365, a selective CDK7 inhibitor, in a panel of high-grade serous ovarian cancer (HGSOC) patient derived xenograft (PDX) models Cancer Research. 79: 4409-4409. DOI: 10.1158/1538-7445.Sabcs18-4409 |
0.365 |
|
2019 |
Johannessen LH, Hu S, Ke N, D'Ippolito A, Rajagopal N, Marineau J, Savinainen A, Zamboni W, Hodgson G. Abstract C091: Preclinical evaluation of PK, PD, and antitumor activity of the oral, non-covalent, potent and highly selective CDK7 inhibitor, SY-5609, provides rationale for clinical development in multiple solid tumor indications Molecular Cancer Therapeutics. 18. DOI: 10.1158/1535-7163.Targ-19-C091 |
0.333 |
|
2018 |
Rajagopal N, Hodgson G, Hu S, McKeown M, Bush A, Fritz C, Orlando D, Olson E, Tomaso Ed. Abstract P1-09-08:BCL2L1(BCL-XL) expression and MYC super-enhancer positivity predict sensitivity to the covalent CDK7 inhibitor SY-1365 in triple negative breast cancer (TNBC) cell lines Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-P1-09-08 |
0.379 |
|
2018 |
Konstantinopoulos PA, Hodgson G, Rajagopal N, Johannessen L, Liu JF, Kirschmeier PT, Zhou S, Tran CA, Orlando D, Fritz C, Tomaso Ed, Matulonis UA. Abstract 1525: SY-1365, a selective CDK7 inhibitor, exhibits potent antitumor activity against ovarian cancer models in vitro and in vivo Cancer Research. 78: 1525-1525. DOI: 10.1158/1538-7445.Am2018-1525 |
0.368 |
|
2017 |
Hu S, Ke N, Ren Y, Miljovska S, Rajagopal N, McKeown M, Orlando D, Sprott K, Choi YJ, Olson E, Fritz CC. Abstract 1151: SY-1365, a potent and selective CDK7 inhibitor, exhibits promising anti-tumor activity in multiple preclinical models of aggressive solid tumors Cancer Research. 77: 1151-1151. DOI: 10.1158/1538-7445.Am2017-1151 |
0.412 |
|
2016 |
Hashimoto TB, Sherwood R, Kang DD, Rajagopal N, Barkal AA, Zeng H, Emons BJ, Srinivasan S, Jaakkola T, Gifford D. A synergistic DNA logic predicts genome-wide chromatin accessibility. Genome Research. PMID 27456004 DOI: 10.1101/Gr.199778.115 |
0.411 |
|
2015 |
Schultz MD, He Y, Whitaker JW, Hariharan M, Mukamel EA, Leung D, Rajagopal N, Nery JR, Urich MA, Chen H, Lin S, Lin Y, Jung I, Schmitt AD, Selvaraj S, et al. Corrigendum: Human body epigenome maps reveal noncanonical DNA methylation variation. Nature. PMID 26605523 DOI: 10.1038/Nature16179 |
0.425 |
|
2015 |
Schultz MD, He Y, Whitaker JW, Hariharan M, Mukamel EA, Leung D, Rajagopal N, Nery JR, Urich MA, Chen H, Lin S, Lin Y, Jung I, Schmitt AD, Selvaraj S, et al. Human body epigenome maps reveal noncanonical DNA methylation variation. Nature. 523: 212-6. PMID 26030523 DOI: 10.1038/Nature14465 |
0.506 |
|
2015 |
Leung D, Jung I, Rajagopal N, Schmitt A, Selvaraj S, Lee AY, Yen CA, Lin S, Lin Y, Qiu Y, Xie W, Yue F, Hariharan M, Ray P, Kuan S, et al. Integrative analysis of haplotype-resolved epigenomes across human tissues. Nature. 518: 350-4. PMID 25693566 DOI: 10.1038/Nature14217 |
0.406 |
|
2015 |
Dixon JR, Jung I, Selvaraj S, Shen Y, Antosiewicz-Bourget JE, Lee AY, Ye Z, Kim A, Rajagopal N, Xie W, Diao Y, Liang J, Zhao H, Lobanenkov VV, Ecker JR, et al. Chromatin architecture reorganization during stem cell differentiation. Nature. 518: 331-6. PMID 25693564 DOI: 10.1038/Nature14222 |
0.454 |
|
2015 |
Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, Ziller MJ, Amin V, Whitaker JW, Schultz MD, Ward LD, ... ... Rajagopal N, et al. Integrative analysis of 111 reference human epigenomes. Nature. 518: 317-30. PMID 25693563 DOI: 10.1038/Nature14248 |
0.462 |
|
2014 |
Rajagopal N, Ernst J, Ray P, Wu J, Zhang M, Kellis M, Ren B. Distinct and predictive histone lysine acetylation patterns at promoters, enhancers, and gene bodies. G3 (Bethesda, Md.). 4: 2051-63. PMID 25122670 DOI: 10.1534/G3.114.013565 |
0.439 |
|
2013 |
Hon GC, Rajagopal N, Shen Y, McCleary DF, Yue F, Dang MD, Ren B. Epigenetic memory at embryonic enhancers identified in DNA methylation maps from adult mouse tissues. Nature Genetics. 45: 1198-206. PMID 23995138 DOI: 10.1038/Ng.2746 |
0.557 |
|
2013 |
Xie W, Schultz MD, Lister R, Hou Z, Rajagopal N, Ray P, Whitaker JW, Tian S, Hawkins RD, Leung D, Yang H, Wang T, Lee AY, Swanson SA, Zhang J, et al. Epigenomic analysis of multilineage differentiation of human embryonic stem cells. Cell. 153: 1134-48. PMID 23664764 DOI: 10.1016/J.Cell.2013.04.022 |
0.487 |
|
2013 |
Rajagopal N, Xie W, Li Y, Wagner U, Wang W, Stamatoyannopoulos J, Ernst J, Kellis M, Ren B. RFECS: a random-forest based algorithm for enhancer identification from chromatin state. Plos Computational Biology. 9: e1002968. PMID 23526891 DOI: 10.1371/Journal.Pcbi.1002968 |
0.463 |
|
2011 |
Tan M, Luo H, Lee S, Jin F, Yang JS, Montellier E, Buchou T, Cheng Z, Rousseaux S, Rajagopal N, Lu Z, Ye Z, Zhu Q, Wysocka J, Ye Y, et al. Identification of 67 histone marks and histone lysine crotonylation as a new type of histone modification. Cell. 146: 1016-28. PMID 21925322 DOI: 10.1016/J.Cell.2011.08.008 |
0.422 |
|
Show low-probability matches. |